Virtus Fund Advisers LLC increased its stake in Humana Inc (NYSE:HUM) by 116.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 423,275 shares of the insurance provider’s stock after acquiring an additional 228,050 shares during the period. Humana makes up approximately 1.0% of Virtus Fund Advisers LLC’s investment portfolio, making the stock its 12th biggest position. Virtus Fund Advisers LLC’s holdings in Humana were worth $105,171,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. WFG Advisors LP boosted its holdings in Humana by 4.5% during the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after buying an additional 20 shares in the last quarter. Advantus Capital Management Inc boosted its holdings in Humana by 1.4% during the third quarter. Advantus Capital Management Inc now owns 14,798 shares of the insurance provider’s stock worth $3,605,000 after buying an additional 203 shares in the last quarter. Cadence Capital Management LLC boosted its holdings in Humana by 3.6% during the third quarter. Cadence Capital Management LLC now owns 5,887 shares of the insurance provider’s stock worth $1,434,000 after buying an additional 205 shares in the last quarter. Daiwa SB Investments Ltd. boosted its holdings in Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after buying an additional 220 shares in the last quarter. Finally, HL Financial Services LLC boosted its holdings in Humana by 2.1% during the fourth quarter. HL Financial Services LLC now owns 11,205 shares of the insurance provider’s stock worth $2,780,000 after buying an additional 230 shares in the last quarter. Institutional investors and hedge funds own 94.13% of the company’s stock.
In other Humana news, SVP Brian P. Leclaire sold 1,679 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total value of $412,983.63. Following the completion of the sale, the senior vice president now owns 9,888 shares in the company, valued at approximately $2,432,151.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Timothy S. Huval sold 1,382 shares of the stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the completion of the sale, the vice president now owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,115 shares of company stock valued at $2,501,627. Insiders own 0.80% of the company’s stock.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The business had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. Humana had a net margin of 4.55% and a return on equity of 16.13%. The firm’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.34 EPS. research analysts forecast that Humana Inc will post 13.86 earnings per share for the current year.
Humana announced that its board has initiated a share repurchase program on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be given a $0.50 dividend. This is an increase from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.74%. Humana’s dividend payout ratio is presently 9.59%.
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 19th. Leerink Swann raised their target price on shares of Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. raised their target price on shares of Humana from $253.00 to $271.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. Jefferies Group upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 target price for the company in a report on Friday, January 12th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $250.00 target price on shares of Humana in a report on Wednesday, February 7th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $270.47.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.